Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Therapeutics Report 2016: Pipeline Review of 4 Companies & 6 Drug Molecules - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016" report to their offering.

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) Delta like ligand 4 (DLL4) is a member of the Delta family of Notch ligands. Delta like ligand 4 is a protein encoded by DLL4 gene. High selective expression pattern of DLL4 is found within the vascular endothelium. DLL4 is upregulated by hypoxia and vascular endothelial growth factor-A (VEGF-A). DLL4 plays a fundamental role in pathological angiogenesis, as blockers of the Dll4 Notch pathway result in decreased tumor growth.

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively.

Delta Like Protein 4 - Pipeline Review, H2 2016, outlays comprehensive information on the Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Delta Like Protein 4 Overview
  3. Therapeutics Development
  4. Pipeline Products for Delta Like Protein 4 - Overview
  5. Pipeline Products for Delta Like Protein 4 - Comparative Analysis
  6. Delta Like Protein 4 - Therapeutics under Development by Companies
  7. Delta Like Protein 4 - Therapeutics under Investigation by Universities/Institutes
  8. Delta Like Protein 4 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Delta Like Protein 4 - Products under Development by Companies
  13. Delta Like Protein 4 - Products under Investigation by Universities/Institutes
  14. Delta Like Protein 4 - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • OncoMed Pharmaceuticals, Inc.
  • PharmAbcine, Inc.
  • Sevion Therapeutics, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/8svdq4/delta_like

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005737/en/

Business Wire
www.businesswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.